About Reviews TB-500
Who keeps this casebook, what "reviews" means on these pages, and the line between reading the evidence and practicing on it.
What this casebook is
Reviews TB-500 is a citation-kept casebook: a page-by-page reading of the peer-reviewed record on TB-500 and its parent protein, thymosin beta-4. The people who keep it are editors and readers of studies, not physicians; nothing here is a diagnosis, a treatment, or advice for a person. Nor is it a storefront — the casebook carries no products, sources no substances, and points to no place to buy. What it does is read the literature and report it plainly.
The casebook form fits this compound because TB-500's literature is, unusually, a mistaken-identity problem. The molecule sold and named TB-500 is the ~889 Da Ac-LKKTETQ heptapeptide [1], but most of the efficacy evidence is on the ~4963 Da full-length protein [5]. Reading those apart — which finding belongs to which molecule — is the whole reason these pages exist.
What "reviews" means on these pages
"Reviews" here has nothing to do with star ratings, vendor rankings, or buying guides. It names a casebook exercise: reconstructing what each study actually measured, what it left untested, and the point where the human-evidence trail runs out. The yardstick is the published record — PubMed, peer-reviewed journals, ClinicalTrials.gov, and FDA primary pages — never anecdote.
Every quantitative claim on these pages ties to a numbered entry in the source register. Where a finding sits on the parent protein rather than the fragment, the sentence says so outright, because that swap is the most common way TB-500 claims get overstated.
Where the casebook stops
This is not a pharmacy, a telehealth desk, or a prescriber. No treatment, consultation, or prescription happens here, and nothing on the site is an offer to sell or supply any substance. The "reviews" in the name marks a stance toward the evidence — a reader of the TB-500 record — not a clinical service of any kind.
The casebook reports what was given to which species, at which dose, by which route. It never turns that into a dose for a person. For the regulatory boundary around access, see the legal-status file; for the limits of the evidence, see the research file. The aim is a record a careful reader can trust and check line by line.
The standard for an entry
A statement earns an entry when it traces to a primary source — a peer-reviewed study, a clinical-trial record, or an FDA primary page — and when the sentence is honest about which molecule the finding sits on. Quantitative claims carry a numbered citation that resolves to a journal, a year, and a DOI or PubMed link in the source register. Where the literature is silent or mixed, the casebook says so plainly rather than papering the gap with confident language.
That rule is why these pages read as a casebook and not a sales sheet. The negative results stay in — the null mdx-mouse strength outcome, the porcine cardiac study that showed no benefit, the non-monotonic stroke dosing — because dropping them would misrepresent the record. Take any figure here, follow its citation, and the same number should be waiting at the source.